Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Philippe Szapary
ResearcherPublications, citations & collaboration network
Philippe Szapary is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 88 works, 10,524 citations, an h-index of 41 and an i10-index of 51.
88
Works
10,524
Citations
41
h-index
51
i10-index
IDs:OpenAlex
How has Philippe Szapary's publication output changed over time?
ScholarIQpublication output · 2003–2019
Output declined50% over the shown period — from 2 works in 2003 to 1 in 2019.
2
2
1
1
1
2
1
1
20032008201220132014201520182019
What are the most-cited papers on Philippe Szapary?
ScholarIQmost cited works
A Randomized Trial of a Low-Carbohydrate Diet for Obesity
Gary D. Foster, Holly R. Wyatt, James O. Hill, Brian G. McGuckin, Carrie Brill, B. Selma Mohammed, Philippe Szapary, Daniel J. Rader, Joel S. Edman, Samuel Klein
New England Journal of Medicine. 20031,795 Citations
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim Papp, Richard G. Langley, Mark Lebwohl, Gerald G. Krueger, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li, Lisa T. Dooley, Kristian Reich
The Lancet. 20081,360 Citations
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
Bruce E. Sands, William J. Sandborn, Remo Panaccione, Christopher D. O’Brien, Hongyan Zhang, Jewel Johanns, Omoniyi J. Adedokun, Katherine Li, Laurent Peyrin‐Biroulet, Gert Van Assche, Silvio Danese, Stephan R. Targan, María T. Abreu, Tadakazu Hisamatsu, Philippe Szapary, Colleen Marano
New England Journal of Medicine. 20191,200 CitationsOPEN ACCESS
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
Kim Papp, C.E.M. Griffiths, Kenneth B. Gordon, Mark Lebwohl, Philippe Szapary, Yasmine Wasfi, Daphne Chan, M.-C. Hsu, Vincent Ho, Pierre‐Dominique Ghislain, Bruce Strober, Kristian Reich, on behalf of the PHOENIX 1, PHOENIX 2 and ACCEPT Investigators
British Journal of Dermatology. 2013410 Citations
Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
Howard Sofen, Stacy Smith, Robert Matheson, Craig L. Leonardi, César A. Calderón, Carrie Brodmerkel, Katherine Li, Kim Campbell, Stanley J. Marciniak, Yasmine Wasfi, Yuhua Wang, Philippe Szapary, James G. Krueger
Journal of Allergy and Clinical Immunology. 2014315 CitationsOPEN ACCESS
Related on ScholarIQ
Cedars-Sinai Medical Center
Institution
A Randomized Trial of a Low-Carbohydrate Diet for Obesity
Paper
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Paper
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
Paper
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
Paper
Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
Paper